Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab, quantity: 75 mg - injection, solution - excipient ingredients: histidine; sucrose; polysorbate 20; water for injections - primary hypercholesterolaemia praluent is indicated as an adjunct to diet and exercise to reduce ldl-c in adults with primary (heterozygous familial or non-familial) hypercholesterolaemia in patients with moderate to very high cardiovascular risk: - in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with maximum tolerated dose of a statin, - alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach ldl-c goals.,prevention of cardiovascular events praluent is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke, unstable angina requiring hospitalisation) in adults with established cardiovascular disease, in combination with optimally dosed statins and/or other lipid-lowering therapies (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab, quantity: 150 mg - injection, solution - excipient ingredients: histidine; sucrose; polysorbate 20; water for injections - primary hypercholesterolaemia praluent is indicated as an adjunct to diet and exercise to reduce ldl-c in adults with primary (heterozygous familial or non-familial) hypercholesterolaemia in patients with moderate to very high cardiovascular risk: - in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with maximum tolerated dose of a statin, - alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach ldl-c goals.,prevention of cardiovascular events praluent is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke, unstable angina requiring hospitalisation) in adults with established cardiovascular disease, in combination with optimally dosed statins and/or other lipid-lowering therapies (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab, quantity: 75 mg - injection, solution - excipient ingredients: histidine; sucrose; polysorbate 20; water for injections - primary hypercholesterolaemia praluent is indicated as an adjunct to diet and exercise to reduce ldl-c in adults with primary (heterozygous familial or non-familial) hypercholesterolaemia in patients with moderate to very high cardiovascular risk: - in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with maximum tolerated dose of a statin, - alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach ldl-c goals.,prevention of cardiovascular events praluent is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke, unstable angina requiring hospitalisation) in adults with established cardiovascular disease, in combination with optimally dosed statins and/or other lipid-lowering therapies (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 200 mg - pessary, shell - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - luteal phase support ? luteal support of assisted reproductive technology (art) cycles,support during pregnancy ? prevention of preterm birth in women with singleton pregnancy who have a short cervix (midtrimester sonographic cervix less than or equal to 25 mm) and/or a history of spontaneous preterm birth. ? treatment of unexplained threatened miscarriage in women with bleeding in the current pregnancy and a history of at least three or more previous miscarriages. use in women with less than three miscarriages may be warranted in those with reduced chances of future pregnancy such as those undergoing ivf treatment with limited viable egg and/or embryo availability or advanced fertility age. however, the benefit of treatment in clinical trials was limited to women with three or more miscarriages. (see section 5 pharmacological properties; clinical trials; threatened unexplained miscarriage)

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 82.26 mg (equivalent: pasireotide, qty 60 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 54.84 mg (equivalent: pasireotide, qty 40 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 27.42 mg (equivalent: pasireotide, qty 20 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -